Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: To develop a novel model for preoperatively predicting the indication for adjuvant radiation therapy after radical prostatectomy according to current guideline recommendations of the European Association of Urology (EAU) based on patient and clinical tumor characteristics in high-risk prostate cancer patients.
Methods: Within a high-volume center database (01/2010-08/2024), we identified high-risk prostate cancer patients. Univariable logistic regression models addressed indication for adjuvant radiation therapy. Multivariable logistic regression models included the most informative, statistically significant preoperative predictors. Harrell's concordance index (c-index) quantified accuracy after 2000 bootstrap resamples for internal validation.
Results: Of 5691 patients, 2137 (38%) had indication for adjuvant radiation therapy according to current EAU guidelines (2025). Indication for adjuvant radiation therapy was associated with higher prostate volume (> 45 cm and 25-45 cm) and advanced tumor characteristics, namely higher prostate-specific antigen value (>20 ng/ml and 10-20 ng/ml), advanced clinical tumor stage (cT3/4 and cT2), lower number of sampled biopsy cores (≤ 12), higher proportion of positive cores (continuous), and higher Gleason Grade Group in biopsy (5, 4, and 3). No association was observed for age and body-mass index and indication for adjuvant radiation therapy. Multivariable model c-index for the prediction of the indication for adjuvant radiation therapy was 0.761 (95% confidence interval 0.749-0.776).
Conclusions: Clinical tumor characteristics can be used for preoperatively predicting the indication for adjuvant radiation therapy after radical prostatectomy according to current EAU guideline recommendations in high-risk prostate cancer patients. Prior to clinical application, the present multivariable model should be externally validated within an independent cohort.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41391-025-01018-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial.
Lancet Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Standard adjuvant chemoradiotherapy (60-66 Gy) following surgery for HPV-associated oropharyngeal squamous cell carcinoma has excellent oncological control but high treatment morbidity. We aimed to compare toxicity of a 30-36 Gy regimen of de-escalated adjuvant radiotherapy and standard of care treatment.
Methods: We did this phase 3, open-label, randomised controlled trial in two academic sites in the USA.
Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model.
Prostate Cancer Prostatic Dis
September 2025
Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.
Background: To develop a novel model for preoperatively predicting the indication for adjuvant radiation therapy after radical prostatectomy according to current guideline recommendations of the European Association of Urology (EAU) based on patient and clinical tumor characteristics in high-risk prostate cancer patients.
Methods: Within a high-volume center database (01/2010-08/2024), we identified high-risk prostate cancer patients. Univariable logistic regression models addressed indication for adjuvant radiation therapy.
Liver transplantation for unresectable colorectal liver metastases: a narrative review.
Chin Clin Oncol
August 2025
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Sloan School of Management and Operations Research Center, Massachusetts Institute of Technology, Boston, MA, USA.
Background And Objective: Liver transplantation (LT) for unresectable colorectal liver metastases (uCRLM) initially showed no clear survival advantage in early attempts, leading to waning enthusiasm. Interest was revived in 2013 following the prospective, non-randomized Norwegian Secondary Cancer (SECA) I study, which reported a 5-year overall survival (OS) of 60%-far surpassing outcomes with systemic therapy alone. More recently, the TransMet randomized controlled trial demonstrated a 5-year OS of 73% in the LT-plus-chemotherapy arm vs.
View Article and Find Full Text PDFNeuraxial anesthesia and pain management for cesarean delivery.
Am J Obstet Gynecol
July 2025
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, CA.
Optimal neuraxial anesthesia for cesarean delivery requires a thorough understanding of patient, obstetrical, surgical, and anesthesia-related factors which can impact pain during and after cesarean delivery. While not all cesarean deliveries are the same from an obstetrical standpoint, not all anesthetics provide the same degree of anesthetic blockade and postcesarean analgesia; therefore, context is crucial to provide patients with a safe and pain-free experience. Communication between obstetrical and anesthesia teams is key to ensure that the anesthetic approach is tailored to the clinical scenario, particularly if emergency cesarean delivery is needed, and follows best practices for cesarean delivery anesthesia.
View Article and Find Full Text PDFFeasibility and Prognostic Analysis of Neoadjuvant Therapy Followed by Breast-Conserving Surgery for Invasive Ductal Carcinoma Combined with Ductal Carcinoma in Situ.
J Invest Surg
December 2025
Department of General Surgery, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, China.
Objective: This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma (DCIS) on pre-NAT biopsy.
Methods: The data of women with IDC who underwent radical surgery between January 2013 and December 2021 were retrospectively reviewed from two institutions. The study endpoints were 5-year disease-free survival (DFS) and local recurrence-fee survival (LRFS).